BSE filing, NSE: NIMBSPROJ. Summary written from the filing by ALFA Finder's alert engine.
Nimbus Projects Ltd: key numbers
- Share price
- ₹185.70
- Market cap
- ₹358.8 Cr
- Revenue (annual)
- ₹228.8 Cr
- Net profit (annual)
- ₹-68.20 Cr
- P/E (TTM)
- -9.0×Sector 34.0×
- Promoter holding
- 70.46%-0.04% QoQ
- FII holding
- 0.06%Current quarter
Reference market data from a third-party provider, updated daily. Not a valuation or a recommendation.
More from Nimbus Projects Ltd
All →Nimbus Projects Board Meeting Date
Nimbus Projects Ltd announced a board meeting for November 5, 2026, to approve Q1 and H1 FY27 results. No financial figures have been disclosed yet.
Nimbus Projects Promoter Reclassification
Nimbus Projects reclassified four individuals from the Promoter category to the Public category, following approval from BSE and NSE. The promoter count reduced from 18 to 14.
Nimbus Projects Acquisition Worth ₹1.02 Cr
Nimbus Projects incorporated its subsidiary, IITL Nimbus The Express Park View Private Limited. The company acquired a 95% stake by converting its Rs.1.02 Crore capital contribution.
- Value
- ₹1.02 Cr
Nimbus Projects Acquisition Worth ₹0.25 Cr
Nimbus Projects Limited incorporated a subsidiary, IITL Nimbus The Hyde Park Private Limited, by converting its ₹0.25 Crore capital contribution in a partnership firm.
- Value
- ₹0.25 Cr
Nimbus Projects Capacity Expansion: ₹15 Cr Investment
Nimbus Projects Limited entered a strategic investment agreement with Sankalp Agencies Private Limited to invest ₹15.00 Crore in a commercial real estate project in New Delhi.
- Value
- ₹15.00 Cr
- From
- Sankalp Agencies Private Limited
- commercial land area
- 6252.6 sq. m.
Nimbus Projects Debt & Borrowing: ₹30 Cr
Nimbus Projects Ltd's board approved availing an unsecured loan of ₹30 Crore from World Resorts Limited. The facility carries an interest rate of 12% per annum.
- Value
- ₹30.00 Cr
- From
- World Resorts Limited
- Execution
- 2 years
Other other announcement announcements
All →Aarti Pharmalabs Other Announcement
Aarti Pharmalabs has intimated under Regulation 46 that it revamped its website at the existing URL to improve design and accessibility. The notice has no financial or business substance.
Sagarsoft (India) Other Announcement
Sagarsoft (India) filed its Regulation 32 fund utilisation statement for its 2021 preferential issue. No deviation was reported and the full Rs.5.08 Crore was used.
Sadhana Nitro Chem Other Announcement
Sadhana Nitro Chem reported no deviation in use of its preferential issue proceeds for the quarter ended September 2026. The Audit Committee reviewed the statement.
Shriram Asset Management Company Other Announcement
Shriram AMC filed ICRA's quarterly monitoring agency report on preferential issue proceeds. Utilisation is in line with the offer objects, with no deviation reported.
Jhandewalas Foods Other Announcement
Jhandewalas Foods filed its quarterly shareholding pattern for the period ended September 30, 2026. The filing records holdings by category and contains no transaction or money event.
Avience Biomedicals Other Announcement
Avience Biomedicals confirmed corporate governance compliance is not applicable, as it is SME-listed on NSE Emerge. No quarterly governance report is required for September 2026.